Which has preferable valuation & earnings, ABOS or IMMP?

Prima BioMed has higher revenue and earnings than Acumen Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.63 N/A Prima BioMed $6.69M 8.04 -$39.78M N/A N/A

Is ABOS or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -136.27% -81.64% Prima BioMed N/A N/A N/A

Does the media prefer ABOS or IMMP?

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 1 articles in the media. Prima BioMed's average media sentiment score of 0.98 beat Acumen Pharmaceuticals' score of 0.00 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, IMMP or KROS?

Keros Therapeutics has higher revenue and earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.04 -$39.78M N/A N/A Keros Therapeutics $244.06M 0.90 $87.01M -$3.70 N/A

Does the media refer more to IMMP or KROS?

In the previous week, Keros Therapeutics had 5 more articles in the media than Prima BioMed. MarketBeat recorded 6 mentions for Keros Therapeutics and 1 mentions for Prima BioMed. Keros Therapeutics' average media sentiment score of 1.61 beat Prima BioMed's score of 0.98 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation & earnings, TNXP or IMMP?

Prima BioMed has lower revenue, but higher earnings than Tonix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tonix Pharmaceuticals $13.11M 17.49 -$124.02M -$12.94 N/A Prima BioMed $6.69M 8.04 -$39.78M N/A N/A

Does the media refer more to TNXP or IMMP?

In the previous week, Tonix Pharmaceuticals had 7 more articles in the media than Prima BioMed. MarketBeat recorded 8 mentions for Tonix Pharmaceuticals and 1 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 0.98 beat Tonix Pharmaceuticals' score of 0.91 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ORGO or IMMP?

Organogenesis has higher revenue and earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organogenesis $564.17M 0.37 $37.03M -$0.86 N/A Prima BioMed $6.69M 8.04 -$39.78M N/A N/A

Which has better valuation & earnings, NBP or IMMP?

Prima BioMed has higher revenue and earnings than I-Mab. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio I-Mab $3.89M 53.51 -$46.27M -$0.36 N/A Prima BioMed $6.69M 8.04 -$39.78M N/A N/A

Is NBP or IMMP more profitable?

Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Prima BioMed N/A N/A N/A

Does the media refer more to NBP or IMMP?

In the previous week, I-Mab had 2 more articles in the media than Prima BioMed. MarketBeat recorded 3 mentions for I-Mab and 1 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 0.98 beat I-Mab's score of -0.39 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prima BioMed (IMMP) Competitors

$0.37 -0.02 (-4.65%)

As of 04:00 PM Eastern

Compare

IMMP vs. ABOS, KROS, TNXP, ORGO, and NBP

Should you buy Prima BioMed stock or one of its competitors? Prima BioMed's main competitors and comparable companies include Acumen Pharmaceuticals (ABOS), Keros Therapeutics (KROS), Tonix Pharmaceuticals (TNXP), Organogenesis (ORGO), and I-Mab (NBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prima BioMed compare to Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 1 articles in the media. Prima BioMed's average media sentiment score of 0.98 beat Acumen Pharmaceuticals' score of 0.00 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acumen Pharmaceuticals currently has a consensus price target of $8.00, suggesting a potential upside of 158.90%. Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,406.44%. Given Prima BioMed's higher possible upside, analysts clearly believe Prima BioMed is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Prima BioMed has higher revenue and earnings than Acumen Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A
Prima BioMed	$6.69M	8.04	-$39.78M	N/A	N/A

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Prima BioMed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Prima BioMed's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%
Prima BioMed	N/A	N/A	N/A

Acumen Pharmaceuticals has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

Summary

Prima BioMed beats Acumen Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Prima BioMed compare to Keros Therapeutics?

Prima BioMed (NASDAQ:IMMP) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Prima BioMed has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Prima BioMed's return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Keros Therapeutics	-256.60%	-21.40%	-19.79%

Prima BioMed has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

Keros Therapeutics has higher revenue and earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.04	-$39.78M	N/A	N/A
Keros Therapeutics	$244.06M	0.90	$87.01M	-$3.70	N/A

In the previous week, Keros Therapeutics had 5 more articles in the media than Prima BioMed. MarketBeat recorded 6 mentions for Keros Therapeutics and 1 mentions for Prima BioMed. Keros Therapeutics' average media sentiment score of 1.61 beat Prima BioMed's score of 0.98 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Prima BioMed presently has a consensus price target of $5.50, suggesting a potential upside of 1,406.44%. Keros Therapeutics has a consensus price target of $20.50, suggesting a potential upside of 84.52%. Given Prima BioMed's higher probable upside, research analysts clearly believe Prima BioMed is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Keros Therapeutics beats Prima BioMed on 8 of the 14 factors compared between the two stocks.

How does Prima BioMed compare to Tonix Pharmaceuticals?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Prima BioMed has lower revenue, but higher earnings than Tonix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	17.49	-$124.02M	-$12.94	N/A
Prima BioMed	$6.69M	8.04	-$39.78M	N/A	N/A

In the previous week, Tonix Pharmaceuticals had 7 more articles in the media than Prima BioMed. MarketBeat recorded 8 mentions for Tonix Pharmaceuticals and 1 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 0.98 beat Tonix Pharmaceuticals' score of 0.91 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tonix Pharmaceuticals has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

Tonix Pharmaceuticals presently has a consensus price target of $24.50, indicating a potential upside of 83.25%. Prima BioMed has a consensus price target of $5.50, indicating a potential upside of 1,406.44%. Given Prima BioMed's higher possible upside, analysts clearly believe Prima BioMed is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Prima BioMed has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Prima BioMed's return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%
Prima BioMed	N/A	N/A	N/A

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Prima BioMed beats Tonix Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Prima BioMed compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

In the previous week, Prima BioMed had 1 more articles in the media than Organogenesis. MarketBeat recorded 1 mentions for Prima BioMed and 0 mentions for Organogenesis. Prima BioMed's average media sentiment score of 0.98 beat Organogenesis' score of -0.48 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Overall Sentiment
Organogenesis	Neutral
Prima BioMed	Positive

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Organogenesis has higher revenue and earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.37	$37.03M	-$0.86	N/A
Prima BioMed	$6.69M	8.04	-$39.78M	N/A	N/A

Organogenesis has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

Organogenesis currently has a consensus price target of $4.33, indicating a potential upside of 164.23%. Prima BioMed has a consensus price target of $5.50, indicating a potential upside of 1,406.44%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Prima BioMed is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Prima BioMed has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Prima BioMed's return on equity of 0.00% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-19.94%	-23.89%	-11.13%
Prima BioMed	N/A	N/A	N/A

Summary

Prima BioMed beats Organogenesis on 10 of the 14 factors compared between the two stocks.

How does Prima BioMed compare to I-Mab?

I-Mab (NASDAQ:NBP) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 3.1% of Prima BioMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Prima BioMed has higher revenue and earnings than I-Mab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	53.51	-$46.27M	-$0.36	N/A
Prima BioMed	$6.69M	8.04	-$39.78M	N/A	N/A

In the previous week, I-Mab had 2 more articles in the media than Prima BioMed. MarketBeat recorded 3 mentions for I-Mab and 1 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 0.98 beat I-Mab's score of -0.39 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

I-Mab has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

I-Mab presently has a consensus price target of $9.00, suggesting a potential upside of 400.00%. Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,406.44%. Given Prima BioMed's higher probable upside, analysts clearly believe Prima BioMed is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Prima BioMed	N/A	N/A	N/A

Summary

Prima BioMed beats I-Mab on 5 of the 9 factors compared between the two stocks.

Get Prima BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMP vs. The Competition

Export

Metric	Prima BioMed	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$56.43M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	N/A	12.66	273.28	25.38
Price / Sales	8.04	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.58	16.29	12.89	6.14
Net Income	-$39.78M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-4.12%	-1.37%	-0.33%	-1.47%
1 Month Performance	-4.02%	11.07%	6.51%	2.47%
1 Year Performance	-77.60%	53.71%	25.19%	15.84%

Prima BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMP Prima BioMed	2.9018 of 5 stars	$0.37 -4.6%	$5.50 +1,406.4%	-76.7%	$56.43M	$6.69M	N/A	2,021	Short Interest Decrease
ABOS Acumen Pharmaceuticals	1.7421 of 5 stars	$3.12 +1.1%	$8.00 +156.8%	+127.9%	$225.27M	N/A	N/A	20
KROS Keros Therapeutics	3.6489 of 5 stars	$11.29 +4.7%	$20.50 +81.5%	-28.6%	$223.92M	$244.06M	N/A	100
TNXP Tonix Pharmaceuticals	4.235 of 5 stars	$12.89 +3.5%	$24.50 +90.1%	-51.6%	$220.99M	$29.10M	N/A	50
ORGO Organogenesis	1.385 of 5 stars	$1.72 +2.7%	$4.33 +152.7%	-65.9%	$220.69M	$564.17M	N/A	950

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMP) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prima BioMed (IMMP) Competitors

IMMP vs. ABOS, KROS, TNXP, ORGO, and NBP

How does Prima BioMed compare to Acumen Pharmaceuticals?

Summary

How does Prima BioMed compare to Keros Therapeutics?

Summary

How does Prima BioMed compare to Tonix Pharmaceuticals?

Summary

How does Prima BioMed compare to Organogenesis?

Summary

How does Prima BioMed compare to I-Mab?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP vs. The Competition

Prima BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prima BioMed (IMMP) Competitors

IMMP vs. ABOS, KROS, TNXP, ORGO, and NBP

How does Prima BioMed compare to Acumen Pharmaceuticals?

Does the media prefer ABOS or IMMP?

Do analysts recommend ABOS or IMMP?

Which has preferable valuation & earnings, ABOS or IMMP?

Do institutionals and insiders hold more shares of ABOS or IMMP?

Is ABOS or IMMP more profitable?

Which has more volatility and risk, ABOS or IMMP?

Summary

How does Prima BioMed compare to Keros Therapeutics?

Is IMMP or KROS more profitable?

Which has more risk and volatility, IMMP or KROS?

Which has stronger earnings & valuation, IMMP or KROS?

Does the media refer more to IMMP or KROS?

Do institutionals & insiders hold more shares of IMMP or KROS?

Do analysts rate IMMP or KROS?

Summary

How does Prima BioMed compare to Tonix Pharmaceuticals?

Which has higher valuation & earnings, TNXP or IMMP?

Does the media refer more to TNXP or IMMP?

Which has more risk & volatility, TNXP or IMMP?

Do analysts rate TNXP or IMMP?

Is TNXP or IMMP more profitable?

Do institutionals & insiders believe in TNXP or IMMP?

Summary

How does Prima BioMed compare to Organogenesis?

Does the media prefer ORGO or IMMP?

Do insiders and institutionals have more ownership in ORGO or IMMP?

Which has better earnings and valuation, ORGO or IMMP?

Which has more risk & volatility, ORGO or IMMP?

Do analysts recommend ORGO or IMMP?

Is ORGO or IMMP more profitable?

Summary

How does Prima BioMed compare to I-Mab?

Do institutionals and insiders hold more shares of NBP or IMMP?

Which has better valuation & earnings, NBP or IMMP?

Does the media refer more to NBP or IMMP?

Which has more volatility and risk, NBP or IMMP?

Do analysts prefer NBP or IMMP?

Is NBP or IMMP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP vs. The Competition

Prima BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools